24 results about "Valerate" patented technology

The invention discloses a pure bio-based polyhydroxyalkanoate adhesive as well as preparation and application thereof, and belongs to the technical field of degradable adhesives. According to the adhesive, polyhydroxybutyrate valerate or polyhydroxybutyrate hexanoate is used as a matrix, and the acid value reaches 2-15 mg KOH / g through molten end group activation; a reactive emulsifier with a hydrophilic-lipophilic balance value of 9-12 is introduced into a water phase, and the stable aqueous dispersion is prepared through phase inversion high-shear emulsification. The Z-average particle size of the dispersion is 0.12-0.30 [mu] m, and the content of the free surfactant is not higher than 30wt%. After the tackifying resin, the plasticizer and the vegetable wax are compounded, the bio-based carbon content of the obtained adhesive is not lower than 95%, and the volatile organic compound content is not higher than 100 mg / kg. The paper / paper heat sealing strength of the adhesive is not lower than 7.0 N / 15mm, the 180-degree peel strength is not lower than 7.5 N / 25mm, and the adhesive can pass repulping evaluation.

A full continuous-flow preparation method of (+)-biotin, including: subjecting a cyclic anhydride and a chiral biphenyl propylene glycol to asymmetric ring-opening reaction to produce a first intermediate, which undergoes selective reduction with a borohydride and cyclization with an inorganic mineral acid to produce (3aS, 6aR)-lactone; subjecting the (3aS, 6aR)-lactone and a sulfenylating reagent to sulfenylation to produce (3aS, 6aR)-thiolactone, which undergoes Fukuyama coupling with a zinc reagent in the presence of a palladium catalyst and elimination reaction in the presence of an inorganic mineral acid to produce an alkenyl valerate compound; subjecting the alkenyl valerate compound to reduction in the presence of a Pd / C catalyst to produce a valerate ester, which undergoes hydrolysis to produce a valeric acid salt; and subjecting the valeric acid salt to debenzylation in the presence of an inorganic mineral acid to produce the target product (+)-biotin.

The application discloses a preparation method of 2-ethyl-2-methyl pentanoic acid, wherein in the process of preparing a key intermediate 2-cyanopentanoate (compound B), compound A is removed by using an alkali extraction method, high-purity compound B is separated by using rectification (a yield of 20% and a purity of 98%), and the operation process is simple. In the preparation method, reagents used are sodium methoxide, sodium hydroxide, sulfuric acid, sodium hydride and sodium nitrite, the reagents are simple, the danger is relatively small, and the experimental operation is relatively safe. In the preparation method, the post-treatment processes of alkylation, hydrolysis, deacidification and cyano hydrolysis do not use a chromatographic column purification process, and a conventional extraction distillation operation is adopted, so that the output of unit volume of instrument equipment is high.

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT·MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT·MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT·EtOH), crystalline 4-glutarato-N,N-DiPT·EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT·EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

The application discloses cupriavidus capable of producing polyhydroxyalkanoate by using various carbon sources such as ethanol and application thereof. Cupriavidus The strain sp.ZWJ01 has a preservation number of CGMCC No.37462 in the China General Microbiological Culture Collection Center. The strain can grow and accumulate poly-3-hydroxybutyric acid ester by using various substances such as ethanol, volatile fatty acid and sugar as carbon sources; can grow by using mixed carbon sources of ethanol+propionic acid or ethanol+valeric acid and accumulate poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid ester) in cells; and can grow by using mixed carbon sources of ethanol+gamma-butyrolactone or ethanol+1,4-butanediol and accumulate poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) in cells, and has a good application prospect.

This invention discloses a method for synthesizing α-hydroxycarboxylic acid compounds. The method includes the following steps: adding a reaction substrate, a photosensitizer, and a base to a dry reaction tube; then adding a solvent and additives under a CO2 atmosphere; and reacting under visible light irradiation. After the reaction is complete, the reaction system is acidified and quenched, and then purified to obtain the product, the α-hydroxycarboxylic acid compound. The photosensitizer includes Ir(ppy)2(dtbbpy)PF6 and 3DPA2FBN; the base is potassium tert-butoxide, cesium carbonate, or potassium tert-valerate; the additives are N,N-diisopropylethylamine and chlorosilane; and the reaction substrate is an aldehyde or ketone compound. This invention provides a highly efficient and selective synthesis of α-hydroxycarboxylic acid compounds under visible light induction and a CO2 atmosphere. The reaction conditions of this invention are mild, the reactant range is broad, the selectivity is good, and it can be scaled up to the gram scale.

This invention belongs to the fields of medicinal chemistry and organic synthesis, specifically relating to a stable 3-aminocyclobutane-1,1-dicarboxylic acid diethyl oxalate and its application in the preparation of 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid. This invention effectively solves the technical bottlenecks of poor stability, difficulty in purification, and storage by converting unstable free 3-aminocyclobutane-1,1-dicarboxylic acid diethyl oxalate into a specific organic acid salt form. More importantly, this invention discovers that this organic acid salt can be directly used as a reaction intermediate, and can be used efficiently in subsequent amide condensation reactions with cholic acid or its active derivatives without the separation of free amines. This method significantly improves the purity and yield of the key intermediate and its downstream product 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid. The process is stable and simple to operate, providing a stable, controllable, and economical preparation route for the industrial production of 3-(cholate-valerate)cyclobutane-1,1-dicarboxylic acid, a key active pharmaceutical ingredient in the liver cancer prodrug LLC-202.

The application discloses a method for preparing methyl valerate by butene carbonylation, and belongs to the field of catalytic chemistry. Raw materials containing butene, carbon monoxide and methanol are introduced into a reactor loaded with a solid acid catalyst, and a product containing methyl valerate is obtained through reaction. The application provides a new method for preparing methyl valerate by butene carbonylation with a solid acid catalyst. The method for preparing methyl valerate has the advantages of cheap and easily obtained raw materials, small corrosion of the system, easy separation of the product, less waste discharge, easy engineering of the fixed bed process, and suitability for single large-scale production.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The invention belongs to the technical field of organic chemistry, and particularly relates to a preparation process of rucotinib phosphate. The preparation process comprises the following steps: carrying out Suzuki coupling reaction on 1-(1-ethoxyethyl)-4-pyrazol boronic acid pinacol ester and (4-chloro-7H-pyrrolo [2, 3-D] pyrimidine-7-yl) methyl pivalate, carrying out acidification treatment, carrying out addition reaction, carrying out chiral resolution treatment, carrying out deprotection treatment, carrying out salt forming reaction and carrying out corresponding post-treatment. According to the preparation process disclosed by the invention, the rucotinib phosphate with high yield and high purity can be prepared.

The present invention relates to an improved process for the preparation of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate Compound (1) or its pharmaceutically acceptable salts thereof. The compound is useful as nucleotide reverse transcriptase inhibitor in therapy for diseases which respond to inhibition of protein kinase activity in humans in need thereof.

The invention discloses a 4-trimethylsiloxy-5-cyano pentanamide / valerate compound and a preparation method of the 4-trimethylsiloxy-5-cyano pentanamide / valerate compound. The preparation method comprises the following steps: directly starting from non-activated olefin alkenyl silane, firstly, carrying out 1, 3-dipolar cycloaddition reaction on the non-activated olefin alkenyl silane and 1, 1-dibromo formaldoxime under the conditions that potassium carbonate is taken as alkali and ethyl acetate is taken as a solvent to generate 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole; then, in a nitrogen atmosphere, by utilizing a photooxidation reduction catalysis strategy and by virtue of the capability of capturing halogen atoms of excited state [Au2 (dppm) 2] Cl2, debromination cracking ring opening of the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole is realized, and alpha-oxy carbon free radicals can be generated in the next free radical 1, 2-silicon migration process, so that the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole can be obtained through debromination cracking ring opening of the 3-bromo-5-(trimethylsilyl)-4, 5-dihydroisoxazole. And the free radical sequentially reacts with acrylamide or acrylic ester and a hydrogen donor to finally obtain the 4-trimethylsiloxy-5-cyano valeramide / valerate compound. The materials required by the method are commercialized or can be prepared through simple organic synthesis, visible light is used as an energy source, the method can be carried out at room temperature, and the method has the characteristics of mild conditions, greenness, environmental protection and the like.

The present application relates to the technical field of phase change material, and provides a phase change cold storage material, a preparation method and application thereof, the phase change cold storage material comprises two or more components; the components comprise ester substances; the ester substances are selected from one or a combination of two or more of butyl valerate, ethyl butyrate and n-propyl acetate. By screening specific ester substances, a mixed medium with a eutectic temperature less than or equal to -90 DEG C can be obtained, so that the energy storage requirement in the temperature zone below -90 DEG C can be realized. The selected substances have the characteristics of high safety and excellent thermal performance, and can be used in the fields of liquefied natural gas storage, liquefied natural gas transportation, medicine storage, medicine transportation or power load management. Meanwhile, the phase change cold storage material preparation method is simple, low in cost and has a high market application prospect.

This invention provides a method for preparing valerate esters by carbonylation of mixed butenes, relating to the field of valerate ester preparation technology. The invention involves pre-preparing a catalyst precursor, ligand, mixed butenes, and an organic solvent with carbon monoxide in a pre-preparation device. The pre-prepared catalyst stream is then continuously fed into a reactor along with mixed butenes, an alcohol, and carbon monoxide for a hydrogen esterification reaction. Simultaneously, a separator separates the valerate ester product, recovers the alcohol, and recycles the catalyst solution. This method achieves efficient and continuous preparation of valerate esters from mixed butenes under mild conditions, offering advantages such as high raw material utilization, long catalyst lifespan, low production cost, and broad prospects for industrial application.

The invention belongs to the field of microorganisms and fermentation engineering, and discloses recombinant escherichia coli for producing valerolactam as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: firstly, modularly optimizing the expression level of a heterologous gene and optimizing a whole-cell catalytic reaction system by using promoter engineering; then, the catabolism of pyruvic acid and the synthesis path of L-lysine are modified, and the supply of precursor substances is enhanced, so that the recombinant escherichia coli realizes de novo synthesis of the valerolactam, and the synthesis efficiency of the valerolactam is remarkably improved. Compared with the prior art, the invention not only provides two methods of whole-cell catalysis and de novo synthesis of the valerolactam, but also effectively avoids the problem of environmental pollution generated in the chemical synthesis process, embodies the concept of green synthesis, and ensures that the yield of the valerolactam reaches a higher level even only at a shake flask level. Important application prospects are provided for efficient synthesis of valerolactam.

The application discloses a kind of acetophenone derivatives and preparation method thereof, belong to organic synthesis field.The acetophenone derivative is 1-[3-methoxy-4-(1-ethyl pentyloxy) phenyl] ethanone, its preparation method includes: anhydrous tetrahydrofuran, 3-heptanol, 4-hydroxy-3-methoxy acetophenone and triphenyl phosphine are mixed, then cooling to 0~10 ℃ and keep in this temperature range drop to it azobisdimethyl valerate, after drop completion room temperature reaction 1~24 hours, again after processing is obtained.The application uses the product that can be easily purchased in market as starting material, and uses relatively safe solvent to carry out reaction, obtains higher reaction yield and high product purity, process flow operation is simple and has no harsh reaction condition, can overcome amplification effect, still maintains higher yield and high purity in kg level production, so as to be more suitable for industrialized production application.

The invention is suitable for the technical field of insect repellent drops, and provides a compound long-acting insect repellent drop and a preparation method thereof, the compound long-acting insect repellent drop comprises an active component, a micro-capsule component, a gel component and a proper amount of water, the mass concentration ratio of the active component to the micro-capsule component to a temperature-sensitive phase change component is (15-20): (22-27): (54-60); the active component comprises a main active component, fipronil and amitraz, and the mass concentration ratio of the main active component to fipronil to amitraz is (6-10): (1-3): (0.2-0.9); the microcapsule component comprises an inner core layer, the inner core layer comprises poly (glycerol sebacate) and polyhydroxybutyrate valerate, and the mass concentration ratio of the poly (glycerol sebacate) to the polyhydroxybutyrate valerate is (3-5): (2-5). According to the invention, the drug effect of the insect repellent drop is obviously prolonged to more than 3 months through a microencapsulation technology, the administration frequency is reduced, and meanwhile, the skin irritation is reduced.

The invention discloses a preparation method of a balofloxacin key intermediate 3-methylaminopiperidine dihydrochloride, which comprises the following steps: carrying out intramolecular condensation on 5-amino-2-((t-butyloxycarboryl) amino) valeric acid serving as an initial raw material under the action of a condensing agent, reducing the obtained lactam under the action of a reducing agent, and purifying to obtain the balofloxacin key intermediate 3-methylaminopiperidine dihydrochloride. And finally, salifying to obtain the 3-methylaminopiperidine dihydrochloride. The method is short in process step, simple and convenient to operate and suitable for large-scale industrial production.

The invention discloses a preparation method of diflucolone or diflucolone valerate, which comprises the following steps: in an inert protective atmosphere, carrying out reduction reaction on flumethasone and a reducing agent in a solvent to obtain the diflucolone, the preparation method comprises the following steps: in an inert protective atmosphere, carrying out acylation reaction on difluorocolone and an acylation reagent in a solvent in the presence of a base catalyst to obtain the difluorocolone valerate. The specific solvent is adopted in the reduction reaction, the problems that in the prior art, reaction by-products are large, raw material reaction is not thorough, the yield is low, and the production cost is high are solved, the product purity and the overall yield are obviously improved, and the production cost is reduced. According to the method, inorganic alkali and acetone are used as a solvent in the acylation reaction, the solvent can be recycled after post-treatment, the method is environment-friendly, 11-site hydroxyl is prevented from being acylated under the acylation condition, byproducts are effectively controlled, and the purity and yield of the product are improved.

This invention relates to the field of agricultural chemical storage stability control technology, and particularly to a carbon steel lined plastic storage tank device and method for storing valerate preparations. The method includes: S1, obtaining initial parameters for the batch to be stored; S2, loading the valerate preparation into the carbon steel lined plastic storage tank and sealing the tank; S3, obtaining detection data sequences of pH value, dissolved oxygen mass concentration, and storage temperature changing over time; S4, establishing a valerate decomposition kinetic model corresponding to the current batch; S5, predicting the predicted mass fraction of the active ingredient in valerate at the end of the planned storage period, and performing a storage condition adjustment step when the predicted mass fraction is lower than a preset lower limit; S6, correcting the parameters of the valerate decomposition kinetic model using the updated detection data sequence. This invention improves storage stability by online monitoring of valerate pH, dissolved oxygen, and temperature, establishing a kinetic model to predict the content at the end of the period, and regulating storage conditions.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, alio-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The invention provides a synthetic method of a prantomanib enantiomer, and belongs to the technical field of chemical synthesis. The method comprises the following steps: taking (S)-3-chloro-1, 2-propylene glycol as an initial raw material, carrying out ring closing reaction under the action of potassium carbonate to generate (S)-glycidol, reacting the (S)-glycidol with pivaloyl chloride to generate (R)-glycidol pivalate, carrying out ring opening reaction on the (R)-glycidol pivalate and 2-bromo-4-nitroimidazole to generate T039-M1-IM1, reacting the T039-M1-IM1 and 4-trifluoromethoxybenzyl bromide to generate T039-M2-IM1, and carrying out ring opening reaction on the T039-M1-IM1 and 4-trifluoromethoxybenzyl bromide to generate T039-M2-IM1. And finally, hydrolyzing the T039-M2-IM1 under the action of potassium carbonate, and carrying out ring closing to generate the pertomanib enantiomer. According to the invention, purification is carried out by adopting water pulping desalination and methyl tert-butyl ether pulping impurity removal, and the purity of the obtained prantomanib enantiomer reaches 99.93%.

The application discloses a pure bio-based polyhydroxyaliphatic acid ester adhesive and preparation and application thereof, and belongs to the technical field of degradable adhesives. The adhesive takes polyhydroxybutyric acid valerate or polyhydroxybutyric acid hexanoate as a matrix, and is subjected to melt end group activation to make the acid value reach 2-15 mg KOH / g; a reaction type emulsifier with a hydrophilic-lipophilic balance value of 9-12 is introduced into an aqueous phase, and a stable water dispersion is prepared through phase inversion high shear emulsification. The dispersion has a Z-average particle size of 0.12-0.30 mu m, and free surfactant is not higher than 30 wt%. After compounding tackifying resin, plasticizer and plant wax, the obtained adhesive has a bio-based carbon content not lower than 95%, and volatile organic compounds not higher than 100 mg / kg. The adhesive has a paper / paper heat sealing strength not lower than 7.0 N / 15 mm, a 180 degree peeling strength not lower than 7.5 N / 25 mm, and can pass re-pulping evaluation.